How many tuberculosis cases will be reported in the United States in 2026?
$0.00
1
5
How many tuberculosis cases will be reported in the United States in 2026?
$0.00
1
5
AI Analysis
Trader mode: Actionable analysis for identifying opportunities and edge
About This Event
2026 If the total number of tuberculosis disease cases reported in the United States during 2026 is above X then the market resolves to Yes. Cases are determined at 10:00 AM ET on the Expiration Date, January 8. Cases that actually occur between the end of the specified time period and Expiration do not count, but newly reported cases during this window do count if they are backdated to 2026. See the full rules for how Source Agencies are prioritized. This market refers exclusively to human cas
What Prediction Markets Are Forecasting
Traders on Kalshi give a 94% chance that the United States will report more than 7,000 tuberculosis cases in 2026. That's roughly a 15 in 16 chance, or about as likely as drawing a red card from a deck that has only one black card in it. This is not a close call. The market is expressing near-certainty that TB cases will stay above that threshold.
To put this in perspective: in 2024, the U.S. reported about 9,600 TB cases. That was the highest number in a decade. A 7,000-case floor for 2026 means traders expect TB to remain a persistent public health concern, not a shrinking one.
Why the Market Sees It This Way
Tuberculosis in the U.S. has been rising slowly since 2020, after decades of steady decline. There are three main reasons traders expect that pattern to hold.
First, TB is a slow-moving disease. It can take years for an infection to become active. People infected during the pandemic-era disruptions to healthcare are still showing up with symptoms now. That backlog hasn't cleared.
Second, global TB rates remain high. The U.S. gets most of its cases from people born abroad who were exposed before arriving. With migration patterns shifting and global TB control programs still recovering from COVID-era setbacks, the import of latent infections continues.
Third, domestic public health infrastructure for TB control has been weakened. Contact tracing, testing, and treatment completion programs lost funding and staff during the pandemic. Many have not fully recovered. TB requires sustained, resource-intensive case management, and that's harder to maintain now.
Key Dates and Events to Watch
The market resolves in early January 2027, when the CDC publishes its final 2026 case count. But signals will come throughout the year. Quarterly CDC reports on TB surveillance are released around March, June, and September. A sharp increase in the first quarter would push odds even higher.
Also watch for any major outbreaks in congregate settings like homeless shelters, prisons, or nursing homes. Those are the environments where TB spreads fastest in the U.S., and a single outbreak can add dozens of cases.
How Reliable Are These Predictions?
Prediction markets are reasonably good at forecasting annual public health statistics, because the data is objective, published with a lag, and follows predictable reporting patterns. The CDC's case counts are not subject to political manipulation or sudden revision.
The main limitation here is that 94% is a very high probability for an event two years out. A lot can change. A new vaccine, improved screening technology, or a major funding push for TB elimination could drive cases down. But the market is betting that none of those things will happen fast enough to matter. Given the slow-moving nature of TB, that's probably a safe bet.
Current Market Outlook
Kalshi traders are pricing a 94% probability that the United States will report more than 7,000 tuberculosis cases in 2026. This is not a close call. The market sees it as nearly certain. For context, the US reported roughly 8,300 TB cases in 2023, down from a post-COVID peak of around 8,500 in 2019 but still well above the 7,000 threshold. The CDC recorded 8,331 provisional cases in 2023. The question is not whether we cross 7,000 but by how much.
Key Factors Driving the Odds
Tuberculosis case counts in the US have been relatively stable for years, fluctuating between roughly 8,000 and 9,500 annually since 2015. The 2020 pandemic dip to 7,174 cases was an outlier driven by lockdowns, reduced travel, and disrupted healthcare access. Cases rebounded to 8,300 by 2023. The 7,000 threshold is roughly 15% below the 2015-2019 average. To fall below it, the US would need a sustained decline that has not materialized in any recent year outside 2020.
The biggest driver is the slow-burn epidemiology of TB. Latent infections reactivate years after initial exposure, and the US has a large pool of people born in high-TB countries. Immigration patterns, particularly from India, the Philippines, and Mexico, keep the reservoir of latent infection steady. CDC data shows about 70% of US TB cases occur in foreign-born individuals. That demographic reality does not change quickly.
What Could Change These Odds
The 6% chance of a No resolution requires an event that cuts case counts sharply. A new highly effective vaccine or a massive screening campaign could do it, but neither is on the near-term horizon. The BCG vaccine has limited efficacy in adults, and no replacement is close to deployment. A severe economic recession could reduce travel and immigration, temporarily lowering case counts, but that would need to be deep and sustained through 2026.
The real risk to the 94% price is a reporting artifact. Kalshi rules count cases backdated to 2026 even if reported after January 8, 2027. But the CDC often revises prior year totals upward as delayed reports trickle in. If 2026 actual cases land just above 7,000, the market resolves Yes. The spread is wide enough that even a modest miss would still clear the bar. The 6% No price reflects pure tail risk, not a plausible base case.
AI-generated analysis based on market data. Not financial advice.
Overview
Tuberculosis (TB) is an infectious disease caused by the bacterium Mycobacterium tuberculosis. It primarily affects the lungs but can also impact other parts of the body. The disease is spread through the air when an infected person coughs, sneezes, or speaks. While TB was once a leading cause of death in the United States, improved living conditions, antibiotics, and public health measures dramatically reduced its incidence over the 20th century. However, TB has not been eliminated. The United States continues to report thousands of cases each year, with recent trends showing a concerning uptick after decades of decline. The prediction market asks how many TB cases will be reported in 2026, reflecting ongoing public health monitoring and the impact of factors like global migration, drug-resistant strains, and disruptions to healthcare systems. Interest in this topic stems from TB's status as a persistent public health challenge. The United States has a goal of TB elimination, defined as less than one case per million people per year, but current rates are far above that. After hitting a historic low of 9,025 cases in 2020, the number of reported cases increased to 7,860 in 2021, 8,300 in 2022, and 9,615 in 2023, according to the Centers for Disease Control and Prevention (CDC). This reversal is partly attributed to delayed diagnoses during the COVID-19 pandemic and increased transmission in congregate settings. The trajectory for 2024 and 2025 will set expectations for 2026, making this a key indicator of whether the U.S. is getting back on track for elimination. Several factors influence annual case counts. International travel and immigration from countries with high TB prevalence, such as India, China, and the Philippines, contribute a significant proportion of U.S. cases. Drug-resistant TB, including multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) strains, complicates treatment and control efforts. Social determinants like poverty, homelessness, and incarceration increase transmission risk. Public health funding and surveillance capacity also play a role. The CDC's Division of Tuberculosis Elimination coordinates national surveillance and response, working with state and local health departments. The prediction market captures uncertainty around how these factors will combine in 2026.
Historical Context
Tuberculosis has a long history in the United States. In the early 20th century, TB was a leading cause of death, with annual mortality rates exceeding 200 per 100,000 people. The development of streptomycin in the 1940s and isoniazid in the 1950s marked the beginning of effective chemotherapy. Combined with public health measures like sanatoriums and contact tracing, TB incidence fell dramatically. By 1985, the U.S. reported 22,201 cases, a decline of over 90% from the 1950s. However, a resurgence occurred between 1985 and 1992, driven by the HIV epidemic, immigration from high-burden countries, and cuts to public health programs. Cases peaked at 26,673 in 1992, prompting a renewed federal investment in TB control. That investment paid off. From 1993 to 2020, TB cases declined steadily at an average rate of about 3.6% per year. The all-time low came in 2020, when 7,174 cases were reported, though this was partly due to decreased healthcare visits during the pandemic. Cases rebounded to 7,860 in 2021, 8,300 in 2022, and 9,615 in 2023. The 2023 figure represented a 16% increase from 2022 and the highest annual count since 2015. This reversal has alarmed public health officials. The CDC's 2023 TB report noted that the rate of TB disease in the U.S. was 2.9 cases per 100,000 persons, up from 2.5 in 2022. Foreign-born individuals accounted for 71% of cases, with a rate of 12.8 per 100,000 compared to 0.8 for U.S.-born persons. The states with the highest case counts were California, Texas, New York, Florida, and Illinois.
Why It Matters
The number of TB cases reported in 2026 matters because it indicates whether the United States is progressing toward TB elimination or backsliding. Each case represents a person who requires months of treatment and can infect others. The economic burden is substantial: treating a single case of drug-susceptible TB costs about $20,000, while a case of MDR-TB can cost over $150,000. If cases continue to rise, healthcare costs will increase, and the goal of elimination will recede further. TB also has social consequences, disproportionately affecting marginalized populations, including the homeless, incarcerated individuals, and immigrants. A rising case count could signal failures in public health infrastructure and health equity. Beyond the United States, U.S. TB trends have global implications. The U.S. is a major funder of international TB programs through agencies like USAID and the Global Fund. If domestic cases rise, political support for global TB funding could wane. Conversely, a successful U.S. elimination strategy could serve as a model for other countries. The prediction market also has practical value for public health planning: accurate forecasts help allocate resources, plan for drug supplies, and prepare healthcare systems. For researchers and policymakers, the outcome will inform decisions about screening policies for immigrants, funding for contact investigations, and strategies for addressing drug resistance. The broader public health community will watch closely to see if the post-pandemic increase is a temporary blip or a new trend.
Educational content is AI-generated and sourced from Wikipedia. It should not be considered financial advice.
